N/A N=175 Preemie Prep For Parents (P3): Home Antenatal Prematurity Education
Premature Birth · Decision Making · Prenatal Care
Primary: Parent Prematurity Knowledge Questionnaire — 30.3; 22.8; 29.3; 25.6 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=54 Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant
Hepatocellular Carcinoma · HCC
Primary: Freedom From Progression Over Time — 0; 3.4; 0; 26.5 percentage of patients with progression
Phase 2 N=43 A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Carcinoid Tumors
Primary: Progression-Free Survival (PFS) — 14.2 months
Phase 2 N=61 JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
Primary Myelofibrosis · Secondary Myelofibrosis
Primary: 2-year Overall Survival (OS) in Patients With Myelofibrosis (MF) Who Receive Treatment With a JAK Inhibitor Followed by an Allogeneic Transplant — 78.24 percentage of…
Phase 2 N=5 Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer
Pancreatic Cancer Non-resectable
Primary: Grade 3 or Higher Adverse Event(s) as a Measure of Safety and Tolerability — 3 Participants
N/A N=36 Preventing Diabetes in the Deep South: Extending Partnerships and Adapting Interventions to Reach Rural Communities at High Risk.
Pre-diabetes
Primary: Change in Body Weight — -3.6; -4.4 Pounds
Phase 2 N=24 A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection
Hepatitis B
Primary: Panel 1 and 2: Absolute Change From Baseline in the Percentage of Hepatitis B Surface Antigen (HBsAg) Hepatocytes at Week 40 — -78.46; -5.68 percentage of HBsAg…
N/A N=60 Improving Physical Activity and Gait Symmetry After Total Knee Arthroplasty
Knee Replacement, Total · Knee Arthroplasty, Total
Primary: Change From Baseline to Month 3 in Objectively Assessed Physical Activity (Accelerometer) — 0.59; 0.36 Minutes per week — p=0.485
Phase 2 N=158 LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
Melanoma
Primary: Overall Response Rate (ORR): Part II — 2.6; 0; 0; 0 Percentage of participants
N/A N=30 Evaluation of ACUVUE® OASYS 1-Day for Astigmatism Contact Lenses With Alternative Lidstock
Ocular Physiology
Primary: Proportion of Eyes With Moderate or Severe Subject-Reported Ocular Symptoms — 0; 0; 0; 0 Proportion of eyes
Phase 2 N=188 A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia
Hypercholesterolemia
Primary: Percent Change in LDL-C From Baseline to Week 12 — -10.59; -21.85; -21.26; -1.92 Percent Change — p=<0.001
N/A N=15 Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study
Neovascular Age-related Macular Degeneration
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 3; 2; 1 Participants
Early Phase 1 N=19 Cough Desensitization Therapy for Cough Hypersensitivity Syndrome
Cough
Primary: Leicester Cough Questionnaire (LCQ) — 3.2; 2.06 score on a scale — p=.23
N/A N=234 An RCT of a Primary Care-Based PTSD Intervention: Clinician-Supported PTSD Coach
Posttraumatic Stress Disorder
Primary: Clinician Administered PTSD Scale for DSM-5 (CAPS-5) — 28.52; 30.01 score on a scale
N/A N=94 The EMPATHY Pilot Study
Leukemia, Chronic Myeloid · Cancer
Primary: Medication Adherence — 7.81 score on a scale